Notícias

RapAdmin

The RIBOGUT trial randomized 105 healthy Dutch adults to placebo, 50 mg/day, or 100 mg/day of oral riboflavin for two weeks, testing whether high-dose vitamin B2 could expand populations of Faecalibacterium prausnitzii, a butyrate-producing gut anaerobe repeatedly linked to gut health. The primary endpoint failed outright. F. prausnitzii abundance did not change by either fluorescence microscopy or 16S sequencing, and neither did overall microbial diversity or community composition. Secondary findings were more interesting. Fecal butyrate concentration rose in the 100 mg group, and rose more convincingly when both riboflavin arms were pooled in a post hoc analysis. Network analysis suggested the bacterial community became more interconnected. A small substudy showed non-significant upward trends in post-glucose insulin and GLP-1 at the higher dose.

The Groningen team had a specific and reasonable hypothesis. Faecalibacterium prausnitzii is one of the most abundant bacteria in the human colon and one of the most consistently depleted in inflammatory bowel disease and obesity. It makes butyrate, the short-chain fatty acid that colon cells burn for fuel and that calms local inflammation. Earlier work had shown that F. prausnitzii uses riboflavin as an electron shuttle, letting it survive in the oxygen gradient near the gut wall where it otherwise would not. Give people enough riboflavin that some escapes absorption in the small intestine and reaches the colon, the logic went, and the bacterium should flourish.

It did not. Across 105 healthy volunteers taking 50 or 100 mg daily for a fortnight, F. prausnitzii numbers held completely flat. Two independent measurement methods agreed. Overall community diversity did not budge either. Where you landed in the microbial map at the start of the trial is where you were at the end.

The riboflavin definitely arrived. Fecal and plasma riboflavin levels climbed steeply in both supplemented groups and not at all in placebo, with some of the most decisive p-values in the paper. So this was not a delivery failure. The vitamin got there and the population census refused to move.

What moved was output. Fecal butyrate rose in the 100 mg group. When the investigators combined both riboflavin arms into a single larger group, a decision made after seeing the data, the butyrate increase became clearer. Acetate rose in the 50 mg group. The bacterial interaction network, a statistical map of which organisms rise and fall together, gained connections and tightened up in the supplemented participants while the placebo network thinned out over the same period.

The interpretation the authors offer is that the same microbial community simply started working differently. More cross-feeding, more metabolic traffic, more butyrate out the far end, with the roster unchanged. Riboflavin is a precursor to FAD and FMN, cofactors that sit at the heart of bacterial electron transport, so a plausible mechanism exists for why handing a community more redox currency would raise its metabolic throughput without changing who belongs to it.

Two cautions matter. The pooling of the dose groups was decided after the fact, which is the kind of analytic choice that generates positive findings from null trials. And the study was funded by DSM Nutritional Products, which employs one author and has since brought a colon-targeted riboflavin ingredient to market built on precisely this concept.

Still, the idea that an inexpensive vitamin might shift gut metabolic function without disturbing gut ecology is worth testing properly. This study is a signal, not a verdict.

Actionable Insights

First, the headline claim is weak but not empty. Pooling both dose groups, fecal butyrate increased from a median of roughly 10 to 11 mM before supplementation to roughly 15 mM after. That is a relative increase in the neighborhood of 35 to 45 percent. Translated into a standardized effect size, the paired comparison corresponds to roughly r = 0.30 to 0.34, which converts to a Cohen’s d somewhere near 0.6 to 0.7. In plain terms, a d of 0.6 means that if you lined up people before and after, the typical person after supplementation sits above about 73 percent of their own pre-supplementation distribution. That is a real but moderate shift, not a transformation.

Second, that number is almost certainly optimistic. It comes from a within-person before-and-after comparison inside a group created after the data were seen. The honest placebo-controlled between-group test of butyrate change was never reported. In the placebo arm, butyrate actually drifted downward over the same window, which means some of the apparent gain is regression to the mean and seasonal or dietary noise rather than drug effect.

Third, be aware. 50 to 100 mg/day is roughly 40 to 90 times the adult RDA. It was safe, and generally is at higher doses like this, but there are not a lot of studies. It will turn your urine bright yellow.

Fourth, if your goal is butyrate, fermentable fiber and resistant starch have substantially stronger and better-replicated human evidence than this. Combining both approaches could be a reasonable strategy.

Context and Source

  • Open Access Paper: Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota
  • Lead institution: Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Journal: Antioxidants & Redox Signaling
  • Country: The Netherlands. Co-affiliations in Australia (University of Adelaide) and Switzerland (DSM Nutritional Products AG, Kaiseraugst, and University Hospital Zurich).
  • Impact Evaluation: The impact score of this journal is 6.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

This review from the University of California, Davis, gathers preclinical, clinical and cell-culture evidence on whether anthocyanins, the red, purple and blue pigments in berries, purple vegetables and pigmented grains, can protect the brain from the damage linked to obesity and high-fat Western diets. The authors argue that the benefits begin in the gut. Very little intact anthocyanin is absorbed, so the compounds act mainly by tightening the intestinal barrier, reducing leakage of bacterial endotoxin into the blood, reshaping the microbiome, and generating phenolic acid metabolites that circulate widely. Further downstream, rodent studies show reduced hippocampal inflammation, preserved BDNF, healthier glucocorticoid signaling and better performance on memory tests. Human data are thinner. Single-meal trials show smaller post-meal spikes in blood fat, glucose and endotoxin, but direct evidence that anthocyanins protect cognition in people with obesity remains inconclusive.

Your brain may care what color your dinner is. That is the idea behind a new review from nutrition scientists at the University of California, Davis, who have pulled together more than a decade of research on anthocyanins, the pigments that make blueberries blue, blackcurrants inky and purple sweet potatoes purple. Their question is narrow but important: can these compounds blunt the harm that obesity and a fat-heavy Western diet inflict on the brain?

The harm itself is well documented. Obesity raises the risk of cognitive decline and dementia, and in rodents a high-fat diet reliably inflames the hippocampus, the brain’s memory hub. One leading explanation starts in the gut. Fatty diets loosen the seals between intestinal cells and change the microbial population, allowing fragments of bacterial cell wall called lipopolysaccharide, or LPS, to slip into the bloodstream. Even a single greasy meal can do this, because LPS hitches a ride on the fat particles absorbed after eating. Circulating LPS stirs up inflammation that can weaken the blood brain barrier and activate the brain’s immune cells.

The twist is absorption. Anthocyanins are poorly absorbed, and usually well under 5 percent of what you eat turns up in urine. For years that looked like a fatal flaw. The UC Davis team argues it is the point. Because most of the pigment stays in the gut, that is where it reaches concentrations high enough to matter. In mouse studies, anthocyanin extracts kept the intestinal barrier intact, reduced LPS leakage, shifted the microbiome toward species such as Akkermansia, and lowered inflammatory markers in the hippocampus. Gut microbes also break anthocyanins down into small phenolic acids, such as vanillic acid, which circulate at far higher levels than the parent compounds and appear to carry some of the benefit.

The review traces several downstream effects. Treated animals kept higher levels of BDNF, a protein that supports learning and neuron survival. Their stress hormone signaling looked healthier. Blood vessels produced more nitric oxide, which may improve blood flow to the brain. In fat tissue, anthocyanins switched on mitochondria-building programs and nudged white fat toward the more metabolically active “beige” type.

In people, the most striking data come from meal challenge studies. When 25 healthy young adults ate a roughly 1,000-calorie high-fat meal with a drink containing about 320 mg of anthocyanins, their post-meal rise in blood fats, glucose and LPS was smaller than with placebo, and BDNF released from blood cells increased. Separately, older adults who ate wild blueberry powder daily for 12 weeks showed better blood vessel function, lower systolic blood pressure and modest gains on some memory tasks.

There are gaps in the research review. Most of the brain evidence comes from short-term studies in young male rodents. Many studies used whole-food extracts loaded with other polyphenols, so the anthocyanins cannot be singled out. And whether anthocyanins protect cognition specifically in people with obesity is, by the authors’ own account, unresolved.

Still, the practical message carries little risk. Eating more deeply colored fruits and vegetables, especially alongside rich meals, is a cheap experiment with a plausible mechanism behind it.

Actionable Insights

Pair rich meals with dark berries. In a crossover trial, about 320 mg of anthocyanins taken with a high-fat meal lowered average blood triglycerides over five hours by roughly 21 percent (about 42 mg/dL lower than placebo).

Aim for about 300 mg of anthocyanins daily, roughly 178 g of fresh wild blueberries (a heaping cup). In older adults this improved artery dilation (FMD) by 0.86 percentage points and lowered 24-hour systolic blood pressure by about 3.6 mmHg over 12 weeks. Pooled data suggest that size of blood pressure drop corresponds to a population-level cardiovascular risk reduction in the single digits of percent.

If you are insulin resistant, blueberry bioactives (about two cups of berries daily) improved insulin sensitivity by 22 percent versus 5 percent on placebo over six weeks. About one extra person in every four treated reached a meaningful improvement.

Expect small lipid changes, not drug-like ones: LDL drops of around 7 mg/dL in pooled trials.

Do not expect a noticeable memory boost. Meta-analyses conflict. If the effect is real, it is small: the average person eating anthocyanins would score better than about 58 to 68 percent of non-eaters on cognitive tests.

Context and Source

  • Paywalled Paper: Anthocyanins and brain health in the context of obesity and Western-style diets, published online 22 October 2026.
  • Institution: Department of Nutrition and Department of Environmental Toxicology, University of California, Davis
  • Country: United States
  • Journal: Archives of Biochemistry and Biophysics
  • Impact evaluation: The impact score of this journal is 3.6 (2025 JIF), evaluated against a typical high-end range of 0 to 50+ for top biochemistry and molecular biology journals, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

This systematic review from Ariel University and collaborating Israeli centers asked whether naturally occurring androgen levels track physical and cognitive performance in healthy middle-aged men. Following PRISMA guidelines with prospective PROSPERO registration, the authors searched three databases for observational studies published between 2010 and 2026, screened 485 records and included 16: seven on physical function and nine on cognition. Free and bioavailable testosterone showed small positive associations with grip strength more consistently than total testosterone, and one longitudinal analysis found higher baseline free testosterone predicted lower risk of mobility limitation over 6.6 years. Cognitive findings were inconsistent across domains, with visuospatial ability showing the most reliable association. Effect sizes were uniformly small, standardized coefficients typically between 0.02 and 0.13.

Testosterone falls by roughly one to three percent per year from a man’s fourth decade onward. Around forty percent of middle-aged men eventually meet a laboratory definition of low testosterone. What that means for how they function has never been clear, because symptoms correlate poorly with the number on the lab report.

A team led by Dan Keren at Ariel University narrowed the question. Rather than asking whether giving men testosterone helps, which has been studied extensively in older and sick populations, they asked whether a man’s own hormone levels in midlife predict how well his body and mind work. They restricted the search to healthy men and to objective measurements: grip strength, walking speed, chair rises, memory tests, processing speed.

Sixteen studies qualified. Seven examined physical performance, nine examined cognition.

The physical side produced the more coherent picture. Across six studies measuring grip strength, free and bioavailable testosterone were associated with stronger grip more consistently than total testosterone. The distinction matters mechanically: most testosterone circulates bound to a carrier protein and is unavailable to tissue, so the free fraction should track biological effect better.

The single longitudinal result is the most useful finding in the review. In the Framingham Offspring cohort, men with higher free testosterone at baseline had a lower risk of developing mobility limitation over the following 6.6 years, with roughly a quarter lower odds. Total testosterone predicted nothing.

The cognitive side was messier. Nine studies, almost no agreement. Visuospatial ability showed the most consistent link to testosterone. Verbal and episodic memory produced contradictory results: one study found higher urinary testosterone predicted better word recall, another found free testosterone predicted worse recall, and a third found the direction depended entirely on a man’s cortisol level.

The size of all of this is the part that gets lost. Standardized coefficients for grip strength clustered between 0.09 and 0.13, meaning testosterone accounted for roughly one to two percent of the differences between men. One walking speed association had a coefficient of 0.02, which is indistinguishable from nothing. The grip strength difference between men with low and normal free testosterone was 2 kilograms, with a confidence interval reaching down to 0.07 kilograms. Typical male grip strength is 40 to 50 kilograms, and the smallest difference people can perceive is usually put at 5 to 6 kilograms.

The authors also report, in their discussion rather than their abstract, the finding that should anchor interpretation. Large randomized trials of testosterone treatment in men with hypogonadism have produced gains in muscle mass and strength but modest and inconsistent effects on actual physical performance, and no cognitive benefit at all.

That gap between observation and intervention is the familiar shape of a confounded association. Men who are more active, leaner and healthier have higher testosterone and also walk faster and grip harder. Fourteen of the sixteen studies measured everything at a single moment, which cannot separate those possibilities.

Actionable Insights

  1. The measurable associations are too small to act on individually. Standardized coefficients for testosterone and grip strength ran from 0.09 to 0.13, accounting for roughly 0.8% to 1.7% of between-person variation. For context, a coefficient of 0.2 is conventionally the floor for a meaningful effect.
  2. The one concrete clinical number is below the threshold people can feel. Men with low free testosterone had grip strength 2.0 kg weaker (95% confidence interval -3.95 to -0.07 kg). The minimal clinically important difference for grip strength is usually cited at 5 to 6 kg, and the upper bound of this interval is essentially zero.
  3. If you are tracking hormones, free or bioavailable testosterone carried the associations more consistently than total testosterone. Note that free testosterone was calculated from total testosterone and binding globulin in nearly every study rather than measured directly, so part of its apparent advantage may be statistical rather than biological.
  4. The longitudinal signal is the most credible: higher baseline free testosterone predicted about 22% lower odds of incident mobility limitation and 25% lower odds of progressive limitation over 6.6 years (odds ratios 0.78 and 0.75). This is one analysis in one cohort of older men.
  5. Treatment does not reproduce the observation. The review cites 2025 evidence that testosterone therapy in hypogonadal men increases muscle mass and strength but has modest, inconsistent effects on physical performance and no cognitive benefit.

Context and Source

  • Paywalled Paper: Endogenous androgens, physical and cognitive function in healthy midlife men: A systematic review
  • Institutions: Faculty of Health Sciences, Department of Physical Therapy, Neuromuscular and Human Performance Laboratory, Ariel University; Division of Maternal Fetal Medicine, Helen Schneider Women’s Hospital, Rabin Medical Center, Petah Tikva; Sheba Longevity Center, Sheba Medical Center, Ramat Gan; Gray Faculty of Medical and Health Sciences, Tel Aviv University; Department of Management, Health Management Program, Bar-Ilan University
  • Country: Israel
  • Journal: Mechanisms of Ageing and Development, volume 234 (2026), article 112257
  • Impact evaluation: The impact score of this journal is 4.9, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

Related Reading

RapAdmin

This study from Aalto University in Finland asked why behavioral studies find semantic skills stable with age while imaging studies report altered brain activity. Forty-six healthy native Finnish speakers, 25 aged 22 to 32 and 21 aged 62 to 69, judged whether word pairs were semantically related. Both groups exceeded 95% accuracy, and the older group responded faster. Brain responses differed substantially. Younger adults showed the canonical N400 effect in left temporal cortex between 300 and 400 milliseconds, followed by a later reversed effect. Older adults showed a weaker, delayed and spatially diffuse response distributed across frontal and bilateral regions. Despite that, machine-learning decoding separated related from unrelated word pairs from roughly 300 milliseconds in both groups, and more strongly in older adults.

Most cognitive abilities decline with age. Semantic knowledge is the stubborn exception. Vocabulary, general knowledge and word associations hold steady or improve into the seventies, a finding so reliable that psychologists treat it as a benchmark of what aging does not take away.

Brain imaging has told a less tidy story. Studies repeatedly find that older adults produce a weaker version of the N400, an electrical response that appears about 400 milliseconds after a word violates expectation. They also find activity shifting from the left temporal lobe toward frontal regions and spreading into both hemispheres. If semantic ability is intact, why does the brain look so different?

A team at Aalto University led by Pietari Nurmi set out to reconcile the two literatures by measuring them in the same people at the same time. Forty-six Finnish speakers, half in their twenties and half in their sixties, lay in a magnetoencephalography scanner and judged whether pairs of words were related. Banana and orange, related. Banana and police, unrelated. Semantic relatedness was defined objectively using a computational language model trained on a 126-million-word corpus of Finnish.

Behavior came out exactly as the semantic literature predicts. Both groups were above 95% accurate. The older adults were not slower. By the raw averages they were about 107 milliseconds faster, which is unusual enough that the authors flag it themselves.

The brain data came out exactly as the imaging literature predicts. Younger adults produced the textbook N400 in left temporal cortex. Older adults produced something later, weaker and smeared across frontal and bilateral regions, with no clean source-level equivalent at all. By conventional measures, their semantic response looked degraded.

The reconciliation came from a different analytic approach. Instead of asking whether a particular response was bigger or smaller, the team trained a classifier to read out, moment by moment, whether the brain was processing a related or an unrelated pair. If the distinction is encoded anywhere in the pattern of activity, the classifier should find it regardless of where that pattern sits.

It found it in both groups, from about 300 milliseconds onward. In older adults it found it more strongly, with classification accuracy peaking around 0.7 compared with 0.6 in younger adults.

That inverts the usual interpretation. The weaker N400 in older adults does not mean the semantic distinction is weaker. It means the distinction has moved somewhere the N400 does not measure well. A response averaged over a specific region at a specific latency will miss information that has been redistributed.

The team also found that within each group, people whose brains separated the two conditions more cleanly responded faster. The correlation was moderate to strong, around 0.65 in younger adults and 0.54 in older adults in the relevant time windows.

Several cautions apply. The sample is small and unusually healthy, screened for cognitive impairment and scoring above age-adjusted norms. The comparison is between people in their twenties and people in their sixties with nobody in between, so it describes a contrast rather than a trajectory. And the headline claim that older adults responded faster does not survive the paper’s own participant-level analysis, where the difference sits at the threshold of significance rather than below it.

Insights

  1. Semantic knowledge is the most age-resistant cognitive domain measured here. The older group matched the younger on vocabulary (p = .287), verbal similarities (p = .283), and both verbal fluency tests (p = .663 and p = .797), while scoring lower on processing speed and visuospatial reasoning. If you are planning around cognitive aging, knowledge-dependent skills are the asset that holds.
  2. Faster responding in older adults was driven by fewer very slow trials, not by uniformly quicker processing. The slow-tail parameter was smaller in older adults (difference about 46 ms, Cohen’s d approximately 0.63, p = .039). The bulk of the distribution was faster by about 63 ms but only marginally so (d approximately 0.59, p = .051). A Cohen’s d of 0.5 is a medium effect, meaning roughly a two-thirds versus one-third split in how the groups fall relative to each other.
  3. Clearer neural representations tracked faster decisions within both groups. In younger adults the correlation between decodability and reaction time was r = -0.65 in the 200 to 400 ms window, accounting for about 42% of the variance in response speed. In older adults the strongest window was 400 to 600 ms at r = -0.54, about 29% of variance. Both confidence intervals are wide at these sample sizes.
  4. A reduced brain response is not automatically a deficit. The older group’s N400 was attenuated, yet the information was more decodable, with classification accuracy of 0.7 versus 0.6 (corresponding to Cohen’s d of roughly 0.74 versus 0.36). This is a useful caution for anyone interpreting EEG or MEG amplitude metrics from consumer or clinical reports.

Context and Source

  • Open Access Paper: Neurophysiological signatures underlying preserved lexical-semantic proficiency in healthy aging
  • Institutions: Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo; BioMag Laboratory, HUS Diagnostic Center, Helsinki University and Helsinki University Hospital; Aalto Neuroimaging, Aalto University
  • Country: Finland
  • Journal: Neurobiology of Aging, volume 170 (2027), pages 1-13
  • Impact evaluation: The impact score of this journal is 4.2, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

RapAdmin

This systematic review from Henan University of Chinese Medicine asked a question the field has mostly skipped: when an intervention lowers someone’s epigenetic age, do their clinical outcomes improve in parallel? The authors searched five databases through August 2026, screened 24,813 records, and included 26 human geroscience trials that measured both a DNA-methylation clock and a clinical outcome before and after treatment. Results were sobering. Fifteen studies showed mixed patterns, six were indeterminate, four were inconclusive, and exactly one, an uncontrolled bariatric surgery study, showed uniform agreement, and only for intermediate measures like weight and HbA1c. No controlled trial and no study of patient-important outcomes such as cognition, frailty or quality of life showed consistent concordance.

Direct-to-consumer biological age tests have become a fixture of the longevity market. Send saliva or blood, receive a number, and often a claim that an intervention has made you biologically younger. The number comes from an epigenetic clock, an algorithm reading chemical tags on DNA at selected sites.

These clocks earned their reputation honestly. Observational studies consistently link accelerated epigenetic age to earlier death, cardiovascular disease and cognitive decline. But a team led by Zhiwan Wang in Zhengzhou noticed that this evidence answers a different question than the one buyers and trialists care about. Predicting who will get sick is not the same as proving that lowering the number makes anyone healthier.

The authors separated four properties that are routinely conflated. Predictive validity asks whether a baseline value forecasts future outcomes. Responsiveness asks whether the clock moves after treatment. Clinical concordance asks whether the clock and the patient’s health move together. Surrogate validity, the highest bar, asks whether the clock change reliably captures the treatment’s effect on health.

They then searched for trials that measured both a clock and a real clinical outcome in the same people. Twenty-six qualified, covering caloric restriction, exercise, metformin, rapamycin, nicotinamide riboside, multivitamins, bariatric surgery, kidney transplantation, plasmapheresis and more.

The pattern was messy. Fifteen trials showed mixed results, meaning some clock-outcome pairs agreed and others contradicted each other within the same study. Six could not be classified because of incomplete reporting. Four showed no clear change in either. One study, bariatric surgery without a control group, showed consistent agreement, and only for weight, waist measurement, insulin resistance and HbA1c.

No controlled trial achieved uniform concordance. No study of cognition, frailty, physical function or quality of life achieved it either.

Individual clocks performed no better. The Horvath clock improved in some weight-loss and exercise studies and worsened in a crossover trial. DunedinPACE slowed with two years of caloric restriction but ran faster after plasmapheresis. GrimAge and PhenoAge varied by study and by outcome.

The explanations are plausible and several are mundane. Blood methylation partly reflects which immune cells are in the sample, and only six of 26 studies clearly adjusted for that. Twenty-two measured the clock within twelve months, which may be too soon for cognition or frailty to change and perhaps too late or too early for methylation. Sixteen studies applied no correction for testing multiple clocks against multiple outcomes. Eight of twelve randomized trials were at high risk of bias, and half the studies had no control group at all.

The authors are careful not to overreach in either direction. They do not claim clocks are useless, and they point out that next-generation clocks remain more predictive and more responsive than older ones. They argue instead that a clock validated in a weight-loss trial tells you nothing about whether it will track cognitive benefit, and that the field should validate one clock, in one context, against one prespecified outcome, rather than measuring as many clocks as possible and reporting whichever moved.

Their bottom line is unusually clean: a reduction in epigenetic age (as measured by today’s biological clocks) should not be described as reversal of aging or clinical rejuvenation.

Actionable Insights

  1. A lower epigenetic age from a consumer test is not evidence that your health improved. Across 26 trials, no controlled study showed consistent agreement between clock improvement and clinical improvement.
  2. Two clocks on the same blood sample can disagree substantially. Applying eight blood-trained clocks to identical samples produced a mean span of 17 years between lowest and highest estimates, with individual spans from 4 to 45 years. Treat a single number as noisy.
  3. Measure function directly instead. Grip strength, gait speed, sit-to-stand repetitions, VO2 max, waist circumference, HbA1c, ApoB and blood pressure all have established links to outcomes and cost almost nothing.
  4. If you retest a clock, keep conditions identical: same lab, same platform, same time of day, same illness and training status. Technical variation alone can shift conventional clock estimates by several years.
  5. The one consistent signal was for intermediate metabolic measures after weight loss. If your goal is metabolic health, measure metabolic health.

Context and Source

  • Open access paper: Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review
  • Institutions: Henan Province Hospital of Traditional Chinese Medicine (Second Affiliated Hospital of Henan University of Chinese Medicine); Lung Disease Diagnosis and Treatment Center, First Affiliated Hospital of Henan University of Chinese Medicine; Collaborative Innovation Center for Chinese Medicine Prevention and Treatment of Respiratory Diseases
  • Country: China
  • Journal: Experimental Gerontology, volume 226 (2026), article 113367
  • Impact evaluation: The impact score of this journal is 4.3, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

RapAdmin

This narrative review from Tongji University in Shanghai argues that the vascular system, meaning arteries, veins and capillaries considered together, acts as a “pioneer organ” that ages early and spreads aging signals to the rest of the body. The authors draw mainly on a 2025 protein atlas of 13 human tissues, a multi-tissue study of aging monkeys, and mouse experiments showing that vesicles from senescent blood vessel cells can damage distant vessels. They propose minimum criteria for diagnosing “panvascular aging,” a decision guide for choosing lab models, and three subtypes (inflammatory, metabolic and mechanical) linked to different candidate therapies. They identify ages 45 to 55 as a key intervention window.

Most of us think of aging organ by organ: a stiff knee, a weakening heart, a forgetful brain. A new review from Tongji University argues that this view misses the plumbing that connects them all. Renhong Lu and Ying-Yu Cui propose that the vascular system, the arteries, veins and capillaries taken together, behaves as a single organ that ages early and spreads that aging to the rest of the body. They call it the pioneer organ hypothesis.

The core evidence comes from a 2025 protein atlas that measured thousands of proteins in 13 tissues from deceased organ donors aged 14 to 68. In that dataset the aorta showed molecular signs of aging from around age 30, earlier than most other organs, and many tissues shifted sharply around age 50. A study of 30 tissues in aging rhesus monkeys likewise placed the aortic arch among the fastest-aging tissues.

How could aging in blood vessels reach distant organs? The authors point to senescent cells, worn-out cells that stop dividing and secrete inflammatory signals. Senescent cells in vessel walls release proteins and tiny membrane packets called extracellular vesicles into the bloodstream. In mice, injecting vesicles from senescent endothelial cells triggered damage in multiple vessel beds. If something similar happens in people, a stiffening aorta is not just a local problem but a broadcaster.

The review then tries to bring order to a messy field. It proposes minimum criteria for calling vascular aging “panvascular”: measurable decline in at least two separate vascular beds, shared circulating signals linking them, and evidence that vascular changes come before organ damage. It offers a guide to which lab models suit which questions, from cell cultures to monkeys. And it sketches three subtypes, inflammatory, metabolic and mechanical, each paired with candidate treatments such as senolytic drugs, NAD+ boosters, or therapies aimed at arterial stiffness.

The practical message is about timing. If vessels age first, the best window for intervention is midlife, roughly 45 to 55, before damage spreads to the heart, brain and kidneys.

That idea has real support from other lines of evidence. Arterial stiffness predicts heart attacks, strokes and death. Midlife blood pressure predicts dementia decades later, and in a large trial, intensive blood pressure control reduced mild cognitive impairment.

The protein atlas it leans on was a single snapshot of different people at different ages, not a study that followed the same people over time, which is how the review describes it. Snapshot data cannot show that one person’s arteries aged before their liver did. The donors were also mostly male and had all died of traumatic brain injury. The diagnostic thresholds and subtypes are the authors’ proposals, not validated tools.

The review is best read as a research agenda. Its central bet, that keeping blood vessels young protects every organ downstream, is plausible and testable. It has not yet been tested.

Actionable Insights

  1. Monitor vascular health early, not after symptoms. Useful measures include home blood pressure, urine albumin-to-creatinine ratio, eGFR, ApoB, and arterial stiffness (carotid-femoral pulse wave velocity, cfPWV) where available. Retinal imaging is an emerging non-invasive window.
  2. Blood pressure control is the best-proven vascular lever. In the SPRINT MIND trial, targeting systolic pressure below 120 cut mild cognitive impairment by 19% (hazard ratio 0.81), about 3.7 fewer cases per 1,000 people per year.
  3. Aerobic exercise lowers arterial stiffness by roughly 0.4 m/s on average. Each 1 m/s rise in cfPWV carries about 14% higher cardiovascular event risk, so this shift corresponds to roughly 5% lower risk, if the relationship is causal.
  4. Women should pay particular attention in the first five years after menopause, when arterial stiffening appears to accelerate.

Context and Source

  • Paywalled Paper: Panvascular aging: The pioneer organ hypothesis, research models and future directions
  • Institution: Tongji University School of Medicine (State Key Laboratory of Cardiology, Shanghai East Hospital; Department of Cell Biology)
  • Country: China
  • Journal: Ageing Research Reviews, volume 123 (2027), article 103378
  • Impact evaluation: The impact score of this journal is 12.4, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Related Reading

RapAdmin

This editorial from the Editor-in-Chief of Age and Ageing and a co-author, is written to launch the journal’s new online collection of vaccine research. It summarizes thirteen previously published papers across three themes. On uptake, it notes that influenza vaccination rates are falling internationally and that successful programs combine clinician education, centralized reminders and easy access, reaching roughly 80 percent in countries like the UK. On effectiveness, it cites a study of nearly 198,000 English care-home residents in which two COVID vaccine doses were 83 to 91 percent effective against death, with protection against infection waning after about 16 weeks. It flags weaker antibody responses in infection-naive residents, a meta-analysis suggesting probiotics boost influenza vaccine responses, and observational data linking several vaccines to lower dementia risk. It closes by calling for care-home residents to be included in future vaccine trials.

Vaccination used to be thought of as something for children. That assumption has eroded steadily, and this editorial from the journal of the British Geriatrics Society argues it should be abandoned entirely. Older adults now have their own recommended vaccine schedule covering influenza, COVID-19, respiratory syncytial virus and pneumococcus, with more in development aimed specifically at this population.

The piece is a curated tour of research the journal has published, written to introduce a new online collection. Its value is as a map rather than as new evidence.

The uptake story is the least complicated. Vaccination rates vary widely between countries and have been falling. Hesitancy is driven by personal beliefs about susceptibility, by family and peer attitudes, and by social and mainstream media. The encouraging finding is that healthcare professionals still carry weight, which places a practical obligation on clinicians to stay current. A network meta-analysis of 22 studies covering 385,182 people found that the combination that works is education, centralized reminder systems and easy physical access to vaccination.

The effectiveness section is where the numbers live. A study of nearly 198,000 care-home residents aged 65 and over in England, tested regularly whether or not they had symptoms, found that a single dose of either vaccine gave moderate protection and a second dose improved it considerably. Against infection, peak effectiveness was 61 percent for the AstraZeneca vaccine and 69 percent for the Pfizer vaccine. Against COVID-related death, the figures were 83 and 91 percent. Protection against infection clearly waned from roughly 16 weeks after the second dose.

Immunology helps explain why. A Spanish study measured antibodies in care-home residents three months after vaccination. Those never previously infected had lower antibody levels than younger adults and markedly weaker virus-neutralizing capacity, barely detectable against the Delta variant. Residents who had been infected showed so-called hybrid immunity, matching or exceeding younger adults. The authors argued boosters should go first to infection-naive residents, and noted that total antibody level is a poor stand-in for actual protection in old age.

Two findings in the piece are more speculative. Ten randomized trials of oral probiotics in 1,560 adults aged 60 and over reported antibody titres about 29 percent higher, with roughly doubled or tripled odds of seroconversion. The editorial concedes that many of those trials were small and at high risk of bias. Separately, a pooled analysis of 21 observational studies covering over 104 million people linked herpes zoster, influenza, Tdap and pneumococcal vaccination to lower dementia risk. A second review found the influenza association held only in high-risk subgroups, and only for vascular dementia, not Alzheimer’s.

The big idea is that vaccination belongs in the healthy-aging toolkit alongside exercise and nutrition, with effects that may reach beyond infection into cardiovascular and cognitive outcomes. The dementia link, though, remains observational, and there is conflicting research.

Actionable Insights

This is a narrative commentary, not primary research. The numbers below come from the studies it cites.

  1. Get vaccinated, and get boosted on schedule. In care-home residents, two doses of COVID vaccine were 83 to 91 percent effective against death. That is a very large effect, far larger than protection against infection alone (61 to 69 percent). Protection against infection waned noticeably from about 16 weeks after the second dose.
  2. If you have never had COVID, boosters matter more. Infection-naive older residents had substantially weaker neutralizing antibody responses than those with prior infection.
  3. Antibody titre is not protection. The cited immunology work found total antibody levels are a poor proxy in older adults, so a high titre on a commercial test should not reassure you.
  4. Probiotics around flu vaccination are plausible but unproven. The pooled odds of seroconversion were 2.74 for H1N1, 1.90 for H3N2 and 1.72 for B strain, with titres about 29 percent higher. These are moderate-to-large effects (Cohen’s d of roughly 0.36 to 0.56), but drawn from small, high-risk-of-bias trials. Low cost, low risk, uncertain benefit.
  5. Do not take a vaccine for dementia prevention. The influenza-dementia association was null in the general population (HR 0.93, CI 0.86 to 1.01) and present only in high-risk subgroups, only for vascular dementia. No trial has tested this.
  6. Ask your clinician. Healthcare professional recommendation is one of the strongest documented drivers of uptake.

Context and Source

  • Paywalled Article: Recent research on vaccines for older adults, 9 October 2026
  • Institutions: University of Aberdeen School of Medicine and NHS Grampian, Aberdeen Royal Infirmary (UK); Saint Camillus International University of Health and Medical Sciences, Rome
  • Countries: United Kingdom and Italy
  • Journal: Age and Ageing (Oxford University Press for the British Geriatrics Society)
  • Impact evaluation: The impact score of this journal is 7.4 (2025 Journal Impact Factor; CiteScore 11.2; ranked 9th of 72 in Geriatrics and Gerontology), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

Researchers analyzed wrist-accelerometer data from 64,743 UK Biobank participants, average age 61.5, followed a median of eight years with 1,697 deaths. They measured two things: total daily steps and peak 30-minute cadence, the average pace during a person’s fastest 30 minutes of the day, which need not be consecutive. Relative to the least active reference group, people taking fewer than 5,000 steps per day but walking at 80 steps per minute had 28 percent lower all-cause mortality risk. People at 5,000 to 7,500 steps walking at only 60 steps per minute had a similar 30 percent reduction. The lowest risk overall occurred at 7,500 to 10,000 steps combined with about 100 steps per minute, at 43 percent lower risk. Cardiovascular mortality followed similar patterns.

The 10,000-step target has no scientific origin. It came from a 1960s Japanese pedometer marketing campaign, and the research community has spent the past decade quietly dismantling it. Recent meta-analyses put most of the mortality benefit between 5,000 and 7,000 steps a day, with diminishing returns after that.

What the field has handled less well is pace. Steps are easy to count and intuitive to communicate. Cadence, the rate at which you take them, is harder, and the evidence has been thinner and less consistent. This new analysis from a Sydney-based group that has produced much of the recent accelerometer-and-mortality literature asks the obvious next question: how do volume and pace interact?

The answer is more interesting than either variable alone. The team sorted participants into four step bands and then modeled mortality risk against cadence within each band. For people in the lowest band, under 5,000 steps a day, the relationship with pace was steep and close to linear. Walking faster conferred progressively more benefit, right up to the limits of what was observed. For people already walking a lot, the curve flattened and then turned up slightly, suggesting that past a certain point extra pace adds nothing.

The practically useful comparison sits between two of those bands. Someone taking under 5,000 steps but moving at 80 steps per minute had roughly the same estimated risk as someone taking 5,000 to 7,500 steps at a relaxed 60 steps per minute. These are two different routes to a similar place. That matters because people fail to exercise for different reasons. Someone short on time can walk briskly. Someone who fears falling, or has knee pain, or simply does not want to rush, can accumulate more steps slowly.

The authors use peak 30-minute cadence, which captures the fastest 30 minutes of the day whether or not those minutes are consecutive. This is a thoughtful choice. It means two minutes of brisk walking to catch a bus, repeated fifteen times across a day, counts the same as a half-hour walk. For older adults who struggle with structured exercise, that framing is more achievable.

The lowest risk of all appeared at 7,500 to 10,000 steps with cadence near 100 steps per minute. One hundred steps per minute happens to be the conventional threshold for moderate-intensity walking, and thirty minutes a day of it works out to roughly 200 minutes a week, comfortably inside the 150 to 300 minute guideline range.

The limits are the usual ones for observational work. People who walk fast are healthier in ways no questionnaire captures, and the authors acknowledge that reverse causation cannot be fully excluded despite their precautions. Several of the headline numbers come from sparse cells with confidence intervals wide enough to include no effect, and the paper’s own abstract highlights one such estimate.

The big idea is that cadence and count are partly interchangeable, which turns a single rigid target into a menu of options.

Actionable Insights

This is a well-conducted observational study. It establishes association, not cause. [Confidence: Medium]

  1. If you walk very little, speed up. Among people under 5,000 steps a day, going from 60 to 80 steps per minute was associated with risk dropping from 0.87 to 0.72, a change of about 15 percentage points. This was the steepest relationship in the entire study.
  2. If you prefer a slow pace, walk more. At 5,000 to 7,500 steps a day, even 60 steps per minute showed a 30 percent lower risk (HR 0.70, CI 0.58 to 0.86), with tighter confidence intervals than the low-step high-cadence estimates.
  3. The target worth aiming at: 7,500 to 10,000 steps per day, with about 100 steps per minute during your fastest 30 minutes. That combination gave the lowest risk in the entire analysis (HR 0.57, CI 0.47 to 0.69).
  4. How to hit 100 steps per minute: it is a brisk walk where you can talk but not sing comfortably. A practical check is roughly 25 steps in 15 seconds. The 30 minutes do not need to be continuous.
  5. Beyond 10,000 steps, faster is not better. The curve flattened and turned up slightly, though the authors note this uptick disappeared in a sensitivity analysis and may be a statistical artifact of sparse data.
  6. Calibrate your expectations. These hazard ratios compare against a very inactive reference group. In a cohort with a 2.6 percent eight-year mortality rate, the headline 43 percent reduction translates to roughly 1.1 percentage points absolute, or one death avoided per 90 people, if causal.

Context and Source

  • Paywalled Paper: Combinations of stepping intensity and daily step counts against all-cause and cardiovascular disease mortality: insights from a device-based prospective study, Sept. 2026.
  • Institutions: School of Health Sciences and Mackenzie Wearables Research Hub, Charles Perkins Centre, University of Sydney; Turner Institute for Brain and Mental Health and Victorian Heart Institute, Monash University; Save Sight Institute; Sydney Local Health District; Universidad Europea de Madrid
  • Countries: Australia (lead), Spain
  • Journal: British Journal of Sports Medicine (BMJ Group, for the British Association of Sport and Exercise Medicine)
  • Impact evaluation: The impact score of this journal is 16.2 (2025 Journal Impact Factor; CiteScore 21; ranked 1st of 133 in Sports Sciences), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

Researchers in Guangzhou designed CardiAdip (CAD), a small molecule intended to activate adiponectin receptors more strongly than the existing compound AdipoRon. In cultured rat heart cells made prematurely senescent with D-galactose, CAD lowered senescence markers and restored mitochondrial respiration. In 24-month-old mice, one month of oral CAD improved ejection fraction, cardiac output, heart size, fibrosis and grip strength, while reducing endoplasmic reticulum stress proteins, mitochondrial fission proteins and the senescence marker p21. Because CAD dissolves poorly in water, the team used exosomes as templates to break CAD crystals into nanoparticles, enabling intravenous dosing. Intravenous dosing at roughly one-thirtieth the cumulative oral dose produced comparable cardiac benefits.

Adiponectin is a hormone released by fat tissue that acts something like an internal exercise signal. It activates AMPK, the cell’s energy sensor, improves insulin sensitivity and supports mitochondrial function. Curiously, leaner people tend to have more of it, and higher levels track with better metabolic health. For two decades, researchers have tried to build a drug that mimics it. The best-known attempt, AdipoRon, works in animals but dissolves so poorly in water that it has never advanced far.

A team at Guangzhou Medical University and the University of Macau set out to improve on both problems at once: a better molecule and a better way to deliver it.

Their compound, CardiAdip, was built by modifying AdipoRon’s chemical skeleton. Computer docking predicted that it binds more tightly to the three main adiponectin-binding proteins on cell surfaces. A protease protection assay supported the idea that the molecule physically engages those proteins. When the researchers silenced all three receptors at once, CAD’s protective effects largely vanished, which argues that the drug is working through the intended target.

The animal results are striking on their face. Twenty-four-month-old mice, roughly equivalent to people in their seventies, showed the expected signs of a failing heart: lower ejection fraction, an enlarged and stiffened left ventricle, extensive scarring and dying heart muscle cells. After one month of daily oral treatment, nearly all of those measures moved substantially toward the values seen in young mice. The animals also hung onto a wire longer, climbed down a pole faster and gripped harder.

Underneath, the molecular story is coherent. Aged hearts showed elevated levels of proteins that signal stress in the endoplasmic reticulum, and elevated DRP1 and FIS1, which fragment mitochondria. They also had more oxidative damage and less cellular energy. CAD reversed each of those, and restored the mitochondrial master regulator PGC-1-alpha. In cells, CAD restored AMPK activation, and blocking AMPK undid much of the benefit.

The formulation work is the paper’s most original contribution. Instead of packaging the drug inside exosomes, where it would have to escape before reaching surface receptors, the team used exosomes and ultrasound to shatter the drug crystals into nanoparticles that stay on the outside. That kept the drug accessible to its membrane targets while making it dispersible in water. The practical payoff was substantial: intravenous dosing at about 8 mg per kilogram per week matched daily oral dosing at 20 mg per kilogram.

The caveats are equally substantial. Binding affinity was predicted by software rather than measured in a binding assay, and the predicted differences from AdipoRon are small enough to fall within docking’s noise. No head-to-head comparison with AdipoRon was run in animals, so there is no evidence that CAD is actually better. Groups contained five mice. Nothing was measured beyond one month, and no survival data exist.

The big idea is that pharmacologically mimicking adiponectin might restore function to an aged heart, and that clever formulation can rescue a drug class that has been stuck on solubility problems. Both deserve attention. Neither is proven in anything other than mice.

Actionable Insights

This is a mouse and cell study. No human has taken this compound.

  1. CardiAdip does not yet exist outside this lab, and AdipoRon is a research chemical not approved for human use.
  2. The pathway it targets is already accessible. Adiponectin levels rise with aerobic exercise, weight loss, fish oil and fiber intake. These remain the only human-validated ways to engage this axis.
  3. The downstream pathway is AMPK. Blocking AMPK abolished the drug’s effect in cells. Exercise, caloric restriction and metformin all activate AMPK, though in humans metformin can blunt gains from training.
  4. How big were the effects? Reading from the figures, ejection fraction in aged mice rose from roughly 45 to 65 percent, back toward the young value of about 68 percent. Fibrotic area fell from about 23 to 8 percent, and heart weight from about 180 to 140 mg. These correspond to effect sizes well above Cohen’s d of 2, which is unusually large and typical of small-group animal studies.
  5. Watch the adiponectin paradox. In humans, high circulating adiponectin predicts worse outcomes in established heart failure, likely reflecting resistance to the signal. Whether a receptor agonist helps or is simply overwhelmed in that setting is unknown.

Safety Data Absent beyond one month in mice.

Context and Source

  • Paywalled Paper: An Adiponectin Receptor Agonist Dispersed via Nonencapsulative Exosomes Alleviates Aging-Associated Cardiac Dysfunction, Published 2026 Sep 2.
  • Institutions: Guangzhou National Laboratory and the First Affiliated Hospital of Guangzhou Medical University (lead), with the University of Macau, Jinfeng Laboratory Chongqing, and the Shenzhen Center for Disease Control and Prevention
  • Country: China
  • Journal: ACS Applied Materials and Interfaces (American Chemical Society)
  • Funding: National Natural Science Foundation of China (82500480 and 82471629), Guangzhou National Laboratory R&D Program, Yu-Yue Scientific Research Center for Pathology. No competing financial interests declared.
  • Impact evaluation: The impact score of this journal is 8.2 (2025 Journal Impact Factor; CiteScore 14.4), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

This invited review from the Mayo Clinic’s Kogod Center on Aging summarizes evidence that senescent cells accumulate in aging skeletal muscle and contribute to weakness, poor regeneration, fibrosis, fat infiltration and insulin resistance. The authors describe three main senescent populations: fibro-adipogenic progenitors that drive fibrosis and inflammation, muscle stem cells that lose regenerative capacity, and long-lived muscle fibers that switch on a p21-driven inflammatory and metabolic program. Human data from muscle biopsies and blood biomarkers link higher senescence burden to lower muscle volume, strength and mobility. In mice, clearing senescent cells with genetic tools or drugs such as dasatinib plus quercetin improves muscle function. The review also covers emerging senolytics, SASP-suppressing drugs, PROTACs and CAR T cells, along with exercise and calorie restriction.

Every adult loses muscle with age. After about 50, mass and strength decline steadily, and for some people the loss becomes sarcopenia and then frailty. Despite decades of research, no drug is approved to prevent or treat age-related muscle loss. A new review in the Annual Review of Physiology argues that a key piece of the puzzle may be senescent cells, sometimes called zombie cells because they stop dividing but refuse to die.

Senescence is a protective response to damage. When a cell’s DNA, telomeres or mitochondria are badly injured, it can lock itself into permanent growth arrest rather than risk becoming cancerous. The problem is that senescent cells do not sit quietly. They secrete a cocktail of inflammatory molecules, enzymes and growth factors known as the senescence-associated secretory phenotype, or SASP. Over time, that cocktail disrupts the tissue around them.

The authors, led by Nathan LeBrasseur, describe how senescence shows up across the cell types that make up muscle. Fibro-adipogenic progenitors, which normally help repair injured muscle, become senescent and pump out inflammatory signals that encourage scarring and fat build-up. Muscle stem cells, the reserve that rebuilds damaged fibers, slip from a reversible resting state into permanent senescence and lose their ability to regenerate tissue. Even the muscle fibers themselves, which never divide, switch on a protein called p21 and begin behaving like senescent cells, with inflammatory output and impaired responses to insulin.

The human evidence comes mainly from large studies of older adults. In the Study of Muscle, Mobility and Aging, muscle biopsies from more than 700 people showed that those with higher senescence signatures had smaller, fattier, weaker muscles and worse physical function. Blood levels of SASP proteins such as GDF-15 and activin A track with frailty and predict who will lose the ability to walk a quarter mile.

Animal studies go further. Clearing senescent cells in mice with genetic tools or with the drug combination dasatinib plus quercetin improves grip strength, endurance and muscle regeneration. Forcing muscle to overexpress p21 does the reverse, causing atrophy and weakness.

The review is strong on biology and candid about gaps. Nobody has yet cleared senescent cells specifically from muscle to test whether they drive sarcopenia directly. Senescence markers are notoriously unreliable, and some cells that look senescent, such as certain macrophages, may simply be activated. Muscle fibers are particularly hard to classify, and the p21 program in fibers overlaps with stress pathways that drive atrophy for other reasons.

The translational picture is less rosy than the review implies. Human trials of senolytics so far have been small, short and mostly focused on other conditions, with mixed results, and none has measured muscle as a primary outcome. One much-publicized natural senolytic, fisetin, failed to reduce senescent cells or extend lifespan in the rigorous NIH Interventions Testing Program.

The big idea is that muscle aging may be driven not only by wear and tear in the fibers but by a small population of dysfunctional cells that poison the neighborhood. For now, the best-supported ways to keep those cells in check are the oldest ones: exercise, especially resistance training, and avoiding excess body fat.

Actionable Insights

This is a review of mechanisms, largely from mouse studies. No senolytic has been shown to improve muscle in humans.

  1. Exercise first. In the authors’ own human studies, structured exercise lowered senescence-related transcripts in blood immune cells and reduced circulating SASP markers. Resistance training reduced senescent cells in fat tissue. Exercise is also the only intervention proven to build muscle in older adults.
  2. Manage body fat. Senescence biomarkers rise stepwise from normal weight to overweight to obesity.
  3. Modest calorie restriction lowered SASP markers in the CALERIE trial, which used about 12 percent restriction for two years. Older adults should weigh this against the risk of losing muscle.
  4. Senolytic drugs are still a work in progress. Human trials of dasatinib plus quercetin have been small, and a 2024 randomized trial in postmenopausal women missed its primary bone endpoint.

How big are the effects? In old mice, senescent cells are cleared about four times more slowly than in young mice. In one key mouse study, dasatinib plus quercetin extended remaining median lifespan by roughly a third, but that result has not been replicated in more rigorous lifespan testing programs. Safety Data Absent for senolytic use in sarcopenia.

Context and Source

  • Paywalled Paper: Cellular Senescence in Skeletal Muscle: Molecular Mechanisms, Physiological Consequences, and Therapeutic Opportunities, published 2026 Oct 21.
  • Institution: Robert and Arlene Kogod Center on Aging; Paul F. Glenn Center for Biology of Aging Research; Department of Physical Medicine and Rehabilitation; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota
  • Country: United States
  • Journal: Annual Review of Physiology (Annual Reviews)
  • Impact evaluation: The impact score of this journal is 20.3 (2025 Journal Impact Factor; second of 89 in Physiology), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.